PPARGC1A and breast carcinoma: Recent studies have also revealed that leptin decreases the cytotoxicity of NK cells against breast cancer cells by upregulating PPARG coactivator 1 alpha (PGC1α), suggesting that targeting leptin or PGC1α could enhance NK-based immunotherapy against breast cancer 87.